The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Assessing a DNAJ-PKAc-targeting therapeutic vaccine in FLC
Marina Baretti, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses a Phase I (NCT04248569) study of a therapeutic vaccine targeting the DNAJ-PKAc chimera in combination with nivolumab and ipilimumab in patients with fibrolamellar hepatocellular carcinoma (FLC). The trial assessed safety and immunogenicity, with most evaluable patients developing T cell responses against the neoantigen. Disease control and partial responses were observed, particularly in those with robust immunologic activation. Findings support further development of neoantigen-directed immunotherapies in this rare cancer. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
